Hepatic steatosis in Iranian patients with chronic hepatitis C

Medical Principles and Practice

Volumn 17, Issue 2, 2008, Pages 126-130

  Minakari, Mohammad ^a,c   Sameni, Farzaneh Khadem ^b   Shalmani, Hamid Mohaghegh ^b   Molaee, Mahsa ^b   Zali, Mohammad Reza ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic hepatitis C; Hepatitis C virus, genotype; Steatosis; Viral load

Indexed keywords

CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; TRIACYLGLYCEROL; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC LIVER DISEASE; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; IRAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS BIOPSY; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; IRAN; LIVER CIRRHOSIS; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTORS; VIRAL LOAD;

EID: 39749157758     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112966     Document Type: Article

References (31)

1. Harrison SA: Steatosis and chronic hepatitis C infection: mechanisms and significance. Clin Gastroenterol Hepatol 2005;3:S92-S96.
2. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP: Steatosis and hepatitis C: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-597.
3. Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM: Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol 2005;100:711-715.
4. Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM: Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003;16:49-56.
5. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N: Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001;21:266-271.
6. Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK: Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol 2005;43:38-44.
7. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L: Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005;41:82-87.
8. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, Dufour JF, Helbling B, Hadengue A, Gonvers JJ, Mullhaupt B, Cerny A, Mondelli MU, Negro F; Swiss Hepatitis C Cohort Study: Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005;42:41-46.
9. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
10. Thomopoulos KC, Theocharis GJ, Tsamantas AC, Siagris D, Dimitropoulou D, Gogos CA, Labropoulou-Karatza C: Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2005;17:149-153.
11. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-490.
12. Harrison SA, Brunt EM, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR: Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005;3:604-609.
13. Brunt EM, Tiniakos DG: Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:691-707.
14. Brunt EM: Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16.
15. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R, Lau JY: New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a and 6a. J Clin Microbiol 1997;35:201-207.
16. Patel K, Zekry A, McHutchison JG: Steatosis and chronic hepatitis C virus infection: mechanisms and significance. Clin Liver Dis 2005;9:399-410.
17. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-1008.
18. Liu CJ, Jeng YM, Chen PJ, Lai MY, Yang HC, Huang WL, Kao JH, Chen DS: Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Antivir Ther 2005;10:405-415.
19. Sheth SB, Gordon FD, Chopra S: Non alcoholic steatohepatitis. Ann Intern Med 1997;126:137.
20. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
21. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379.
22. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA: Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-2961.
23. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-372.
24. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
25. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T: Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123.
26. Hosseini-Moghaddam SM, Keyvani H, Kasiri H, Kazemeyni SM, Basiri A, Aghel N, Alavian SM: Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran: a multicenter study. J Med Virol 2006;78:569-573.
27. Adinolfi LE, Utili R, Andreana A, Tripodi MF, Marracino M, Gambardella M, Giordano M, Ruggiero G: Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 2001;46:1677-1683.
28. Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM: Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004;11:455-458.
29. Romero-Gomez M, Castellano-Megias VM, Grande L, Irles JA, Cruz M, Nogales MC, Alcon JC, Robles A: Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003;98:1135-1141.
30. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr, Zarski JP, Borisch B, Hadengue A, Negro F: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-115.
31. Negro F: Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006;12:6756-6765.